RxDoctor Payments Data

Debra Kime, PA

Medical · Macon, GANPI 1114982709

Payments from drug & device makers

$5,500in general payments, 2019–2025

Across 275 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$717
  • Takeda Pharmaceuticals U.S.A., Inc.$607
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$440
  • Gilead$391
  • Pfizer$210
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$5,476100%
  • Education$100%
  • Gifts$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,500 in reported general payments places this provider in the 85th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$56,764
Medicare patients
355
Services billed
595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin15$53,040
CreonLipase/Protease/Amylase12$35,127
LinzessLinaclotide24$20,608
Mesalamine18$11,831
CholestyramineCholestyramine (With Sugar)34$2,034
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl142$2,023
Sucralfate54$1,555
Pantoprazole Sodium140$1,387
Famotidine121$1,378
Omeprazole126$1,191
Lactulose46$879
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl51$855
Cyproheptadine Hcl26$670
ConstuloseLactulose14$668
EnuloseLactulose14$557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,611$55,73436 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$440$53,04015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 950 medical providers in Georgia.

Other medical in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →